Examples of using Halaven in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What is Halaven?
What HALAVEN looks like and contents of the pack.
Other information about Halaven.
How is Halaven used?
What is the risk associated with Halaven?
What is Halaven used for?
HALAVEN 0.44 mg/ml solution for injection Eribulin.
What benefit has Halaven shown during the studies?
HALAVEN is usually given on Days 1 and 8 of every 21-day cycle.
Adverse reaction after previous HALAVEN administration.
How has Halaven been studied?
For the full list of all side effects reported with Halaven, see the package leaflet.
Why has Halaven been approved?
HALAVEN may cause side effects such as tiredness(very common) and dizziness common.
The most commonly reported adverse reactions related to HALAVEN, are bone marrow suppression manifested as neutropenia, leucopenia, anaemia, thrombocytopenia with associated infections.
HALAVEN was not studied in patients with severe hepatic impairment Child-Pugh C.
The administration of HALAVEN should be delayed on Day 1 or Day 8 for any of the following.
HALAVEN must not be used during breast-feeding because of the possibility of risk to the child.
Using aseptic technique HALAVEN can be diluted up to 100 ml with sodium chloride 9 mg/ml(0.9%) solution for injection.
HALAVEN is a clear, colourless aqueous solution for injection provided in glass vials containing 2 ml or 3ml of solution.
For more details on the use of Halaven including recommendations on dose reduction, see the summary of product characteristics also part of the EPAR.
HALAVEN contains the active substance eribulin and is an anti-cancer medicine which works by stopping the growth and spread of cancer cells.
In the first study, when comparing Halaven with all the other treatments grouped together, Halaven was shown to be more effective at prolonging life.
HALAVEN may cause adverse reactions such as tiredness and dizziness which may lead to minor or moderate influence on the ability to drive or use machines.
The efficacy of HALAVEN in breast cancer is primarily supported by two randomized Phase 3 comparative studies.
Halaven is also used to treat adults with advanced or metastatic liposarcoma(a type of cancer of the soft tissues that develops from fat cells) that cannot be surgically removed.
One example is eribulin(Halaven®), which has been approved since 2010 in the treatment of metastatic breast cancer and represents a synthetic analogue of the sponge metabolite halichondrin B.
When Halaven was used as breast cancer second-line therapy(after at least one previous cancer treatment for advanced/metastatic disease), Halaven was a valuable treatment option similar to capecitabine and with an acceptable safety profile.
The third study showed that Halaven was effective at prolonging life in patients with liposarcoma: patients treated with Halaven lived for an average of 15.6 months, compared with 8.4 months for patients treated with dacarbazine.
Additionally, Halaven prolonged the length of time that liposarcoma patients lived, and this was considered important as these patients have limited treatment options.